Bicycle Therapeutics PLC
BCYC· Nasdaq
Released Feb 20, 2024, before the open
10-K filed Feb 20, 2024, 51 days after period end · 0001558370-24-001324
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $5.33M | $3.19M | $3.77M | $3.85M |
| Net Income | -$49.10M | -$29.98M |
Bicycle Therapeutics PLC · CIK 1761612 · Engraved from SEC EDGAR
| -$18.04M |
| -$17.43M |
| EPS Diluted | — | — | — | -$0.83 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.